Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Nanobiotix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NANO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: NANO's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: NANO exceeded the French Biotechs industry which returned 31.1% over the past year.
Return vs Market: NANO exceeded the French Market which returned 42% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Nanobiotix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StIf You Had Bought Nanobiotix (EPA:NANO) Stock A Year Ago, You Could Pocket A 126% Gain Today
4 months ago | Simply Wall StHow Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?
6 months ago | Simply Wall StWould Shareholders Who Purchased Nanobiotix's (EPA:NANO) Stock Three Years Be Happy With The Share price Today?
Is Nanobiotix undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NANO is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: NANO is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NANO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NANO is overvalued based on its PB Ratio (6x) compared to the FR Biotechs industry average (4.4x).
How is Nanobiotix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NANO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NANO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NANO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NANO's revenue (57.1% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: NANO's revenue (57.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NANO is forecast to be unprofitable in 3 years.
How has Nanobiotix performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NANO is currently unprofitable.
Growing Profit Margin: NANO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NANO is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.
Accelerating Growth: Unable to compare NANO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NANO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: NANO has a negative Return on Equity (-47.67%), as it is currently unprofitable.
How is Nanobiotix's financial position?
Financial Position Analysis
Short Term Liabilities: NANO's short term assets (€125.2M) exceed its short term liabilities (€19.0M).
Long Term Liabilities: NANO's short term assets (€125.2M) exceed its long term liabilities (€44.5M).
Debt to Equity History and Analysis
Debt Level: NANO's debt to equity ratio (60.7%) is considered high.
Reducing Debt: NANO's debt to equity ratio has increased from 28.9% to 60.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NANO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NANO has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 16.8% each year
What is Nanobiotix current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NANO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NANO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NANO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NANO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NANO's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Laurent Levy (47 yo)
Mr. Laurent Lévy, Ph.D. has been the President of the Executive Board at Nanobiotix S.A. since May 27, 2004 and its Chief Executive Officer since March 2003. Mr. Lévy has a thorough understanding of the te...
CEO Compensation Analysis
Compensation vs Market: Laurent's total compensation ($USD993.95K) is above average for companies of similar size in the French market ($USD557.80K).
Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.
Experienced Management: NANO's management team is considered experienced (4.6 years average tenure).
Experienced Board: NANO's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 53.2%.
Nanobiotix S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Nanobiotix S.A.
- Ticker: NANO
- Exchange: ENXTPA
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €440.383m
- Shares outstanding: 34.81m
- Website: https://www.nanobiotix.com
Number of Employees
- Nanobiotix S.A.
- 60 rue de Wattignies
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enha...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 17:58|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.